References

1. National Osteoporosis Foundation.

2. Bouxsein ML, Marcus R. Overview of exercise and bone mass. Rheum Dis Clin North Am. 1994;20:787-802.

3. NIH Consensus Statement 2000.

4. Reginster JL. Treatment of bone in elderly subjects: calcium, vitamin D, fluoride, bisphosphonates, calcitonin. Horm Res. 1995; 43:83-

5. NIH Consensus Development Panel on Optimal Calcium Intake. Optimal calcium intake. JAMA. 1994; 272:1942-8.

6. Clinical Pharmacology 2000. Gold Standard Multimedia

7. American Association of Clinical Endocrinologists 2001, Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis

8. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA. 1999 Apr 28;281(16):1505-11.

9. Lesser GT. Vitamin D deficiency in women with hip fracture. JAMA. 2000 Mar 15;283(11):1425-6.

10. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998 Mar 19;338(12):777-83.

11. Chapuy MAC, Argot ME, Duboeuf F et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992; 327:1637-42.

12. Dawson-Hughes B, Harris SS, Krall EA et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-6

13. Medical Crossfire

13a. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003;326(7387):469.

14.14. Iqbal MM. Osteoporosis: epidemiology, diagnosis, and treatment. South Med J. 2000 Jan;93(1):2-18.

15. Watts NB. Treatment of osteoporosis with bisphosphonates. Rheum Dis Clin North Am. 1994; 20:717-34.

16. Merck & Co., Inc.,Whitehouse Station, NJ 08889, USA. Fosamax package insert, October 2000.

17. Black DM, Cummings SR, Karpf DB, etal. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996 Dec 7;348(9041):1535-41.

18. Cummings SR, Black DM, Thompson DE, etal. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998 Dec 23-30;280(24):2077-82.

19. Ensrud KE, Black DM, Palermo L et al. Treatment with alendronate prevents fractures in women at highest risk. Arch Intern Med. 1997;157:2617-24.

20. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, etal. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA. 1997 Apr 9;277(14):1159-64.

21. Homik J, Cranney A, Shea B, Tugwell P, etal. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev. 2000;(2):CD001347.

22. Saag KG, Emkey R, Schnitzer TJ, Brown JP, etal. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998 Jul 30;339(5):292-9.

23. Pols HA, Felsenberg D, Hanley DA, Stepan J, etal. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group. Osteoporos Int. 1999;9(5):461-8.

24. Orwoll E, Ettinger M, Weiss S, Miller P, etal. Alendronate for the treatment of osteoporosis in men.N Engl J Med. 2000 Aug 31;343(9):604-10.

25. Kung AW, Yeung SS, Chu LW. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study. Calcif Tissue Int. 2000 Oct;67(4):286-90.

26. Bone HG, Adami S, Rizzoli R, Favus M, etal. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther. 2000 Jan;22(1):15-28.

27. Baran D. Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly. Geriatrics. 2001 Mar;56(3):28-32.

28. Schnitzer T, Bone HG, Crepaldi G, Adami S, etal. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000 Feb;12(1):1-12.

28a. Ascott-Evans BH, Guanabens N, Kivinen S et al. Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial. Arch Intern Med. 2003 Apr 14;163(7):789-94.

29. Harris ST, Watts NB, Genant HK, McKeever CD, etal. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999 Oct 13;282(14):1344-52.

30. McClung MR, Geusens P, Miller PD, Zippel H, etal. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001 Feb 1;344(5):333-40.

30a. Actonel package insert. Cincinnati, OH: Procter & Gamble Pharmaceuticals; 2002.

31. Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, etal. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab. 2000 May;85(5):1783-8.

32. Drugs for prevention and treatment of postmenopausal osteoporosis. Med Lett Drugs Ther. 2000 Oct 16;42(1090):97-100.

33. Hochberg M. Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. Drugs Aging. 2000 Oct;17(4):317-30. Review.

34. Chesnut CH 3rd, Silverman S, Andriano K, Genant H,etal. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000 Sep;109(4):267-76.

35. Cummings SR, Chapurlat RD. What PROOF proves about calcitonin and clinical trials. Am J Med. 2000 Sep;109(4):330-1. 

36. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, Miacalcin Nasal Spray, Package Insert, 1999.

37.Grady D, Rubin SM, Petitti DB et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 117:1016-37.

38. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, etal. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992 Jul 1;117(1):1-9.

39. Black DM. Why elderly women should be screened and treated to prevent osteoporosis. Am J Med. 1995; 98(suppl. 2A):67S-75S.

40. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA. 1997 Feb 19;277(7):543-7.

41. Cauley JA, Seeley DG, Ensrud K, Ettinger B, etal. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995 Jan 1;122(1):9-16.

42. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, etal. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995 Jun 15;332(24):1589-93.

43. Lindsay R, Bush TL, Grady D, Speroff L, etal. Therapeutic controversy: Estrogen replacement in menopause. J Clin Endocrinol Metab. 1996 Nov;81(11):3829-38.

44. Sagraves R. Estrogen therapy for postmenopausal symptoms and prevention of osteoporosis. J Clin Pharmacol. 1995; 35:2S-10S.

45. Evans MP, Fleming KC, Evans JM. Hormone replacement therapy: management of common problems. Mayo Clin Proc. 1995 Aug;70(8):800-5.

46. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, etal. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997 Dec 4;337(23):1641-7.

47. Snyder KR, Sparano N, Malinowski JM. Raloxifene hydrochloride. Am J Health Syst Pharm. 2000 Sep 15;57(18):1669-75.

48. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, etal. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999 Aug 18;282(7):637-45.

49. Cummings SR, Eckert S, Krueger KA, Grady D, etal. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999 Jun 16;281(23):2189-97.

50. Altkorn D, Vokes T. Treatment of postmenopausal osteoporosis. JAMA. 2001 Mar 21;285(11):1415-8.

51. Clinical Pharmacology 2003. Gold Standard Multimedia.

52. Bell NH, Termine JD. Treatment and prevention of osteoporosis: future directions. J S C Med Assoc. 2001 Mar;97(3):99-101

53. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-1441

return to top of page